Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

M6A modification regulates cell proliferation via reprogramming the balance between glycolysis and pentose phosphate pathway

ABSTRACT: N6-methyladenosine (m6A) stands as the predominant modification in eukaryotic mRNA and is involved in various biological functions. Aberrant m6A has been implicated in abnormal cellular phenotypes, including defects in stem cell renewal and tumorigenesis. However, the precise effects of m6A on cell proliferation and the underlining mechanism of metabolic gene regulation remain incompletely understood. Here, we established a cellular environment with low-m6A levels and observed a severe impairment of cell proliferation. Mechanistic studies revealed that the depletion of m6A on TIGAR mRNA led to increased expression, subsequently inhibiting glycolysis while promoting the pentose phosphate pathway (PPP). A genome-wide CRISPR-Cas9 screen identified extensive genes involved in cell proliferation that are affected by m6A modification, with G6PD emerging as a key regulator. Integration of gene expression and survival data from LIHC patients suggested specific subsets with elevated G6PD expression may exhibit enhanced responsiveness to tumor growth inhibition through m6A suppression. Our findings elucidate the critical role of m6A in cellular metabolic regulation, particularly in the metabolic reprogramming of cell proliferation, offering new insight for cancer therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE261509 | GEO | 2025/03/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Nuclear TIGAR mediates an epigenetic-metabolic loop via Nrf2 for cancer therapeutics resistance

Project description:Epigenetic and metabolic reprogrammings are implicated in cancer progression with unclear mechanisms. We report here that the histone methyltransferase NSD2 drives cancer cell and tumor resistance to therapeutics such as tamoxifen, doxorubicin, and radiation by reprogramming of glucose metabolism. NSD2 coordinately up-regulates expression of TIGAR, HK2 and G6PD and stimulates pentose phosphate pathway (PPP) production of NADPH for ROS reduction. We discover that elevated expression of TIGAR, previously characterized as a fructose-2,6-bisphosphatase, is localized in the nuclei of resistant tumor cells where it stimulates NSD2 expression and global H3K36me2 mark. Mechanistically, TIGAR interacts with the antioxidant regulator Nrf2 and facilitates chromatin assembly of Nrf2-H3K4me3 methylase MLL1 and elongating Pol-II, independent of its metabolic enzymatic activity. In human tumors, high levels of NSD2 correlate strongly with early recurrence and poor survival and are associated with nuclear-localized TIGAR. This study defines a nuclear TIGAR-mediated, epigenetic autoregulatory loop functioning in redox rebalance for resistance to tumor therapeutics. A total of 4 samples were analyzed in this study. The study included two cell lines, MCF7 and the tamoxifen-resistant subline TMR. Both were were cultured in medium containing vehicle control and/or 4-hydroxytamoxifen (Tam). The untreated MCF7 and TMR cell lines served as controls for the study.

2016-10-22 | E-GEOD-62613 | biostudies-arrayexpress

Nuclear TIGAR mediates an epigenetic-metabolic loop via Nrf2 for cancer therapeutics resistance

2016-10-22 | GSE62613 | GEO

m6A modification regulates cell proliferation via reprogramming the balance between glycolysis and pentose phosphate pathway

Project description:m6A modification regulates cell proliferation via reprogramming the balance between glycolysis and pentose phosphate pathway

| PRJNA1087349 | ENA

METTL3 Confers Oxaliplatin Resistance Through the Activation of G6PD-enhanced Pentose Phosphate Pathway in Hepatocellular Carcinoma

Project description:Oxaliplatin-based therapeutics is a widely used treatment approach for hepatocellular carcinoma (HCC) patients; however, drug resistance poses a significant clinical challenge. Epigenetic modifications have been implicated in the development of drug resistance. In our study, employing siRNA library screening, we identified that silencing the m6A writer METTL3 significantly enhanced the sensitivity to oxaliplatin in both in vivo and in vitro HCC models. Further investigations through combined RNA-seq and non-targeted metabolomics analysis revealed that silencing METTL3 impeded the pentose phosphate pathway (PPP), leading to a reduction in NADPH and nucleotide precursors. This disruption induced DNA damage, decreased DNA synthesis, and ultimately resulted in cell cycle arrest. Mechanistically, METTL3 was found to modify E3 ligase TRIM21 near the 3'UTR with N6-methyladenosine, leading to reduced RNA stability upon recognition by YTHDF2. TRIM21, in turn, facilitated the degradation of the rate-limiting enzyme of PPP, G6PD, through the ubiquitination-proteasome pathway. Importantly, high expression of METTL3 was significantly associated with adverse prognosis and oxaliplatin resistance in HCC patients. Notably, treatment with the specific METTL3 inhibitor, STM2457, significantly improved the efficacy of oxaliplatin. These findings underscore the critical role of the METTL3/TRIM21/G6PD axis in driving oxaliplatin resistance and present a promising strategy to overcome chemoresistance in HCC.

2024-08-23 | GSE241802 | GEO

Gene expression profiling of Human Hepatocellular Carcinoma tissues

Project description:Hepatocellular carcinoma (HCC) is the fifth most common malignancy of cancer-related deaths worldwide, and prognosis of patients with HCC still remain unsatisfactory. Therefore, more reliable biomarkers for predicting the disease and understanding the mechanisms underlying cancer development need to be found out urgently. In this study, we explored the clinical significance and role of ALDOB, G6PD in HCC pathogenesis. Here we show that low ALDOB expression with high G6PD expression lead to patients' poor survival and prognosis by remodeling metabolic pathway and increasing tumor proliferation and metastasis. Stat5a regulates ALDOB expression positively but negatively to G6PD expression in mRNA level, simultaneously, ALDOB inhibits G6PD enzymatic activity by protein-protein interaction and we have found one of their interaction sites in ALDOB. These data suggest that ALDOB and G6PD could be potential biomarkers for HCC. We analyzed tissues from 5 hepatocellular carcinoma patients using the GeneChip PrimeView Human Gene Expression Array. Affymetrix microarray assays were performed according to the manufacturer's directions on total RNA isolated from patients' tissues. Array data was processed by Affymetrix Exon Array Computational Tool. No techinical replicates were performed.

2015-11-04 | E-GEOD-74656 | biostudies-arrayexpress

m6A RNA Methylation Is Regulated by MicroRNAs and Promotes Reprogramming to Pluripotency

Project description:N6-methyladenosine (m6A) has been recently identified as a conserved epitranscriptomic modification of eukaryotic mRNAs, but its features, regulatory mechanisms, and functions in cell reprogramming are largely unknown. Here, we report m6A modification profiles in the mRNA transcriptomes of four cell types with different degrees of pluripotency. Comparative analysis reveals several features of m6A, especially gene- and cell-type-specific m6A mRNA modifications. We also show that microRNAs (miRNAs) regulate m6A modification via a sequence pairing mechanism. Manipulation of miRNA expression or sequences alters m6A modification levels through modulating the binding of METTL3 methyltransferase to mRNAs containing miRNA targeting sites. Increased m6A abundance promotes the reprogramming of mouse embryonic fibroblasts (MEFs) to pluripotent stem cells; conversely, reduced m6A levels impede reprogramming. Our results therefore uncover a role for miRNAs in regulating m6A formation of mRNAs and provide a foundation for future functional studies of m6A modification in cell reprogramming. m6A-seq in ESC, iPSC, NSC and sertoli cells.

2015-03-10 | E-GEOD-52125 | biostudies-arrayexpress

TimeLapse-seq reveals that ALKBH5 modulates RNA stability of metabolic transcripts

Project description:N6-methyadenosine (m6A) RNA modification controls numerous cellular processes through regulation of RNA stability and translational efficiency. Whether the RNA m6A modification regulates energy metabolism process by posttranscriptional regulation is unknown. We here show that loss of the m6A demethylase ALKBH5 results in instability of oxogluatarate-dehydrogenase (Ogdh) messenger RNA and transcripts of other metabolic enzymes.

2023-02-01 | GSE194148 | GEO

Gene expression profiling of Human Hepatocellular Carcinoma tissues

2015-11-04 | GSE74656 | GEO

METTL3-dependent m6A modification programs human neural progenitor cell proliferation

Project description:METTL3-dependent m6A modification programs human neural progenitor cell proliferation

| PRJNA1013796 | ENA

Effects of Exogenous N6-methyladenosine (m6A) Incorporation on the Expression of Cellular mRNA Transcripts

Project description:N6-methyladenosine (m6A) is the most prevalent and reversible internal mRNA modification in eukaryotic cells, and plays an essential role in RNA fate determination. In this work, we studied the exogenous incorporation of m6A into cellular mRNA through salvage pathway and evaluated its resultant biological effects. First, we found that feeding of HeLa cells with m6A nucleoside significantly altered cell morphology and viability. We then synthesized isotope-labelled d3-m6A (N6-methyl-d3-adenosine) and examined the d3-m6A incorporation rate in cellular mRNA along with incubation time using mass spectrometry. Next, RNA sequencing (RNA-seq) was used to study the biological effects of exogenous m6A incorporation. Finally, thousands of genes were found to be differentially expressed, and were dramatically enriched in pathways such as ribosome biogenesis, mRNA metabolic process and cell morphogenesis differentiation. All these results suggested that exogenous m6A could be incorporated into mRNAs through a metabolic pathway to influence cellular gene expression.

2022-04-25 | GSE201293 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data